Brokerages Set Prothena Corp. (PRTA) PT at $76.80
Prothena Corp. (NASDAQ:PRTA) has received a consensus rating of “Buy” from the six research firms that are currently covering the stock. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $76.80.
PRTA has been the topic of a number of recent research reports. Royal Bank Of Canada restated a “buy” rating on shares of Prothena Corp. in a research note on Wednesday, June 22nd. Wedbush restated an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research note on Tuesday, July 5th. Barclays PLC boosted their target price on Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, August 4th. Credit Suisse Group AG restated a “buy” rating and issued a $65.00 target price on shares of Prothena Corp. in a research note on Sunday, September 11th. Finally, Zacks Investment Research downgraded Prothena Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, October 4th.
In other news, insider Arthur W. Homan sold 3,125 shares of the company’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $52.16, for a total transaction of $163,000.00. Following the completion of the sale, the insider now owns 3,125 shares in the company, valued at approximately $163,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Karin L. Walker sold 12,000 shares of the company’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $61.10, for a total value of $733,200.00. Following the sale, the insider now owns 7,000 shares of the company’s stock, valued at approximately $427,700. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Prothena Corp. by 197.8% in the first quarter. BlackRock Inc. now owns 2,656 shares of the company’s stock valued at $110,000 after buying an additional 1,764 shares in the last quarter. Societe Generale acquired a new position in Prothena Corp. during the second quarter valued at $111,000. BNP Paribas Arbitrage SA boosted its position in Prothena Corp. by 49.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,039 shares of the company’s stock valued at $141,000 after buying an additional 1,344 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Prothena Corp. by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 4,021 shares of the company’s stock valued at $141,000 after buying an additional 493 shares in the last quarter. Finally, Emerald Acquisition Ltd. acquired a new position in Prothena Corp. during the second quarter valued at $195,000.
Shares of Prothena Corp. (NASDAQ:PRTA) opened at 53.55 on Wednesday. Prothena Corp. has a 12-month low of $28.20 and a 12-month high of $76.42. The stock’s market capitalization is $1.84 billion. The firm’s 50-day moving average price is $57.27 and its 200 day moving average price is $49.19.
Prothena Corp. (NASDAQ:PRTA) last issued its earnings results on Tuesday, August 2nd. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by $0.27. Prothena Corp. had a negative net margin of 8,628.11% and a negative return on equity of 28.15%. The firm earned $0.33 million during the quarter, compared to analysts’ expectations of $0.39 million. The business’s quarterly revenue was up 22.2% compared to the same quarter last year. Analysts predict that Prothena Corp. will post ($4.25) EPS for the current fiscal year.
About Prothena Corp.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related companies with MarketBeat.com's FREE daily email newsletter.